α1-Adrenoceptor subtypes and lower urinary tract symptoms

Authors


  • Grant Support: Funded in part by NIH grants #AG00745 and #AG17566 (DAS).

Debra A Schwinn md, Department of Anesthesiology, Box 356540, University of Washington, 1959 NE Pacific Street, Room BB1461, Seattle, WA 98195-6540, USA. Email: dschwinn@u.washington.edu

Abstract

Abstract:  Benign prostatic hyperplasia (BPH) is a common cause of urinary outflow obstruction in aging men leading to lower urinary tract symptoms (LUTS). α1-Adrenoceptors (α1ARs) antagonists (blockers) have become a mainstay of LUTS treatment because they relax prostate smooth muscle and decrease urethral resistance, as well as relieving bladder LUTS symptoms. A review of key recent clinical trials suggests new insights into the role of specific α1AR subtypes in the treatment of LUTS.

Ancillary